Quintiles Chief: Australia Needs To Back Investment In Medical Research
This article was originally published in PharmAsia News
Executive SummaryThe CEO of Quintiles Transnational Corp. says Australia is well-placed to take advantage of China's growing R&D, biotech and pharmaceutical investments
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.